Biothera Pharmaceuticals Announces Presentation of Clinical Data Supporting Use of a Patient Selection Biomarker for its Phase 2 Cancer Immunotherapy EAGAN, Minn., Feb. 24, 2017 (GLOBE NEWSWIRE) -- Biothera Pharmaceuticals, Inc. will present data today from all cohorts (total N=36) enrolled in a healthy human volunteer study of Imprime PGG, the...

Biothera Pharmaceuticals Initiates Patient Dosing in Phase 2 Trial Investigating Imprime PGG and Merck’s KEYTRUDA® (pembrolizumab) EAGAN, Minn., Feb. 23, 2017 (GLOBE NEWSWIRE) -- Biothera Pharmaceuticals, Inc. today announced that dosing has been initiated in a Phase 2 clinical trial evaluating Biothera’s Imprime PGG in...

Biothera Pharmaceuticals to Discuss Imprime PGG Combination Therapy with Checkpoint Inhibitors at Molecular Medicine Tri-Conference 2017 EAGAN, Minn., Feb. 15, 2017 (GLOBE NEWSWIRE) -- Biothera Pharmaceuticals, Inc. today announced that it will deliver two presentations on its Phase 2 candidate Imprime PGG at the 24th annual...

Biothera Pharmaceuticals and Merck Further Expand Research Collaboration to Include Phase 2 Clinical Trial in Head and Neck Cancer EAGAN, Minn., Dec. 05, 2016 (GLOBE NEWSWIRE) -- Biothera Pharmaceuticals, Inc. today announced an expansion of its research collaboration with Merck (known as MSD outside the United States and...